MTIC

MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity [1][2][3][4].

Product Specifications

CAS Number

[3413-72-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/mtic.html

Purity

99.51

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(/N=N/NC)N=CN1)N

Molecular Formula

C5H8N6O

Molecular Weight

168.16

Precautions

H302, H315, H319, H335

References & Citations

[1]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163. |[2]Nagasawa HT, et al. The mechanism of alkylation of DNA by 5- (3-methyl-1-triazeno) imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388) . Non-involvement of diazomethane. Chem Biol Interact. 1974 Jun;8 (6) :403-13.|[3]Tsang LL, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl- (triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27 (5) :342-6.|[4]Beal DD, et al. Carcinogenicity of the antineoplastic agent, 5- (3,3-dimethyl-1-triazeno) -imidazole-4-carboxamide, and its metabolites in rats. J Natl Cancer Inst. 1975 Apr;54 (4) :951-7.